EdwardJ.GorakIIDOMBA MS FACP

Oncology • Jacksonville, FL

Vice President, Medical Director of Operations Baptist Physician Enterprise, Baptist Health

Join to view full profile

Dr. Gorak is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Connect with other colleagues in the same hospital or clinic
Search all U.S. specialist profiles and refer a patient
Read the latest clinical news and earn CME/CEU credits

See Dr. Gorak's full profile

Already have an account?

Office
1301 Palm Avenue
Jacksonville, FL 32207
Phone+1 904-202-7300
Is this information wrong?

Summary

Interests in organizational development and organizational behavior compliment clinical interests

Education & Training

Pennsylvania State UniversityM.B.A., Business, 2012 - 2014
National Capital ConsortiumFellowship, Hematology and Medical Oncology, 2003
Tripler Army Medical CenterResidency, Internal Medicine, 1995 - 1998
Tripler Army Medical CenterInternship, Internal Medicine, 1995 - 1996
University of New England College of Osteopathic MedicineClass of 1995

Certifications & Licensure

FL State License 2015 - 2026
LA State License 2015 - 2016
PA State License 2005 - 2016
MD State License 1998 - 2000

Awards, Honors, & Recognition

CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2011-2013

Clinical Trials

Pentostatin, Cyclophosphamide, and Rituximab Followed By Campath-1H in Patients With Relapsed or Refractory B-Cell CLL Start of enrollment: 2005 Apr 14
Completed
Phase 2
Rituximab and Combination Chemotherapy in Treating Patients With Diffuse Large B-Cell Non-Hodgkin's Lymphoma Start of enrollment: 2005 May 01
Completed
Phase 3
Combination Chemotherapy and Alemtuzumab in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia Start of enrollment: 2006 Jun 01
Terminated
Phase 2
Azacitidine With or Without Entinostat in Treating Patients With Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, or Acute Myeloid Leukemia Start of enrollment: 2006 Aug 01
Completed
Phase 2
S0535, Gemtuzumab and Combination Chemotherapy in Treating Patients With Previously Untreated Acute Promyelocytic Leukemia Start of enrollment: 2007 Nov 15
Completed
Phase 2
Combination Chemotherapy in Treating Young Patients With Newly Diagnosed Acute Lymphoblastic Leukemia Start of enrollment: 2008 Mar 12
Active, not recruiting
Phase 2
Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic Leukemia Start of enrollment: 2008 Jan 15
Completed
Phase 2
Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
Daunorubicin, Cytarabine, and Midostaurin in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2008 Apr 01
Active, not recruiting
Phase 3
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma Start of enrollment: 2009 Jul 01
Completed
Phase 2
Lenalidomide With or Without Epoetin Alfa in Treating Patients With Myelodysplastic Syndrome and Anemia Start of enrollment: 2009 Jan 29
Active, not recruiting
Phase 3
Collecting Tissue Samples From Patients With Leukemia or Other Blood Disorders Planning to Enroll in an ECOG Leukemia Treatment Clinical Trial Start of enrollment: 2004 Sep 21
Completed
Chemoembolization With or Without Sorafenib Tosylate in Treating Patients With Liver Cancer That Cannot Be Removed by Surgery Start of enrollment: 2009 Oct 28
Completed
Phase 3
Phase III Randomized Trial of Clofarabine as Induction and Post-Remission Therapy vs. Standard Daunorubicin & Cytarabine Induction and Intermediate Dose Cytarabine Post-Remission Therapy, Followed by Decitabine Maintenance vs. Observation in Newly-Diagnos Start of enrollment: 2011 Jan 01
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant Start of enrollment: 2010 Sep 01
Terminated
Phase 2
Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis Start of enrollment: 2010 Nov 01
Completed
Phase 3
Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702) Start of enrollment: 2010 May 01
Completed
Phase 3
Lenalidomide or Observation in Treating Patients With Asymptomatic High-Risk Smoldering Multiple Myeloma Start of enrollment: 2011 Jan 24
Active, not recruiting
Phase 3
Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma Start of enrollment: 2011 Feb 09
Completed
Phase 2
S1106 Rituximab With Combination Chemotherapy or Bendamustine Hydrochloride Followed by Consolidation Chemotherapy and Stem Cell Transplantation in Older Patients With Previously Untreated Mantle Cell Lymphoma Start of enrollment: 2011 Nov 01
Completed
Phase 2
Azacitidine With or Without Lenalidomide or Vorinostat in Treating Patients With Higher-Risk Myelodysplastic Syndromes or Chronic Myelomonocytic Leukemia Start of enrollment: 2012 Mar 01
Active, not recruiting
Phase 2
Cytarabine and Daunorubicin Hydrochloride or Idarubicin and Cytarabine With or Without Vorinostat in Treating Younger Patients With Previously Untreated Acute Myeloid Leukemia Start of enrollment: 2013 Feb 12
Completed
Phase 3
Rituximab and Combination Chemotherapy With or Without Lenalidomide in Treating Patients With Newly Diagnosed Stage II-IV Diffuse Large B Cell Lymphoma Start of enrollment: 2013 Aug 27
Active, not recruiting
Phase 2
Rituximab and Bendamustine Hydrochloride, Rituximab and Ibrutinib, or Ibrutinib Alone in Treating Older Patients With Previously Untreated Chronic Lymphocytic Leukemia Start of enrollment: 2013 Dec 09
Active, not recruiting
Phase 3
Phase II Randomized Trial Comparing GA101 and Rituximab in Untreated Low Tumor Burden Indolent Non-Hodgkin's Lymphoma Start of enrollment: 2013 Dec 01
Terminated
Phase 2
Ibrutinib and Rituximab Compared With Fludarabine Phosphate, Cyclophosphamide, and Rituximab in Treating Patients With Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma Start of enrollment: 2014 Feb 20
Active, not recruiting
Phase 3
Clofarabine or Daunorubicin Hydrochloride and Cytarabine Followed By Decitabine or Observation in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia Start of enrollment: 2011 Feb 04
Active, not recruiting
Phase 3
Join now to see all

Publications & Presentations

PubMed

Discordant pathologic diagnoses of myelodysplastic neoplasms and their implications for registries and therapies.
Edward J Gorak, Michael Otterstatter, Tareq Al Baghdadi, Nancy Gillis, James M Foran, Jane Jijun Liu, Rafael Bejar, Steven D Gore, Steven H Kroft, Alexandra Harrington...> ;Blood Advances. 2023 Oct 24
12 citations
North American Blastic Plasmacytoid Dendritic Cell Neoplasm Consortium: position on standards of care and areas of need.
Naveen Pemmaraju, Hagop Kantarjian, Kendra Sweet, Eunice Wang, Jayastu Senapati, Nathaniel R Wilson, Marina Konopleva, Arthur E Frankel, Vikas Gupta, Ruben Mesa, Matth...> ;Blood. 2023 Feb 9
2 citations
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorship.
Issam I Raad, Ray Hachem, Nigo Masayuki, Tarcila Datoguia, Hiba Dagher, Ying Jiang, Vivek Subbiah, Bilal Siddiqui, Arnaud Bayle, Robert Somer, Ana Fernández Cruz, Edwa...> ;Elife. 2023 Jan 30
10 citations
The National MDS Natural History Study: design of an integrated data and sample biorepository to promote research studies in myelodysplastic syndromes.
Mikkael A. Sekeres, Steven D. Gore, Donald M. Stablein, Nancy L. DiFronzo, Gregory A. Abel, Amy E. DeZern, Jesse D. Troy, Dana E. Rollison, John W. Thomas, Myron A. Wa...> ;Leukemia & Lymphoma. 2019 May 21
113 citations
Metformin Is Associated With Survival Benefit in Cancer Patients With Concurrent Type 2 Diabetes: A Systematic Review and Meta-Analysis
Ming Yin, Jie Zhou, Edward J. Gorak, Fahd Quddus> ;The Oncologist. 2013 Dec 1
46 citations
Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
James R. Berenson, Ori Yellin, Alberto Bessudo, Ralph V. Boccia, Stephen J. Noga, Donald S. Gravenor, Dipti Patel-Donnelly, Robert S. Siegel, Tarun Kewalramani, Edward...> ;British Journal of Haematology. 2013 Feb 1
Efficacy and safety of bendamustine plus bortezomib in relapsed/refractory multiple myeloma: A phase I/II trial.
Berenson JR, Yellin O, Bessudo A, Boccia R, Noga S, Gravenor D, Patel-Donnelly D, Siegel RS, Kewalramani T, Gorak EJ, Swift R, Bensen-Kennedy D> ;J. Clin. Oncol.. 2011-05-20
2 citations
Unusual warm autoimmune hemolytic anemia in non-alcoholic steatohepatitis.
Fouad N. Boctor, Edward J. Gorak, Jeffrey W. Prichard, Masoud Firouzi, William Difilippo> ;Annals of Clinical and Laboratory Science. 2008 Jun 20
3 citations
Erythema nodosum secondary to granulocyte colony-stimulating factor in a patient with Hodgkin lymphoma during CD34+ cell mobilization for autologous peripheral blood s...
Susan George, Benjamin George, Edward Gorak> ;Biology of Blood and Marrow Transplantation. 2005 Oct 1
46 citations
Engraftment syndrome after nonmyeloablative allogeneic hematopoietic stem cell transplantation: incidence and effects on survival.
Edward Gorak, Nancy L. Geller, Ramaprasad Srinivasan, Igor Espinoza-Delgado, Teresa Donohue, A. John Barrett, Anthony F. Suffredini, Richard W. Childs> ;Biology of Blood and Marrow Transplantation. 2005 Jul 1
76 citations
Safety, tolerability, and lack of antibody responses after administration of a PfCSP DNA malaria vaccine via needle or needle-free jet injection, and comparison of int...
Judith E. Epstein, Edward J. Gorak, Yupin Charoenvit, Ruobing Wang, Nicole Freydberg, Oluwatoyin Osinowo, Thomas L. Richie, Erin L. Stoltz, Fernando Trespalacios, John...> ;Human Gene Therapy. 2002 Sep 1
186 citations
Induction of CD4+ T cell-dependent CD8+ type 1 responses in humans by a malaria DNA vaccine
Ruobing Wang, Judith E. Epstein, Fe Maria Baraceros, Edward J. Gorak, Yupin Charoenvit, Daniel J. Carucci, Richard C. Hedstrom, Nancy Rahardjo, Peter Hobart, Rick Stou...> ;Proceedings of the National Academy of Sciences of the United States of America. 2001 Sep 11
263 citations
Community-acquired methicillin-resistant Staphylococcus aureus in hospitalized adults and children without known risk factors.
Edward J. Gorak, Stephen M. Yamada, Joel D. Brown> ;Clinical Infectious Diseases. 1999 Aug 15
189 citations
A communitywide perspective of sex differences and temporal trends in the incidence and survival rates after acute myocardial infarction and out-of-hospital deaths cau...
Robert J. Goldberg, Edward J. Gorak, Jorge L. Yarzebski, David W. Hosmer, Priscilla Dalen, Joel M. Gore, Joseph S. Alpert> ;Circulation. 1993 Jun 1
Join now to see all

Press Mentions

Baptist Health 'Health Care Heroes' from Jacksonville to Be Honored During Super Bowl LVFebruary 8th, 2021

Professional Memberships

American Society of Clinical Oncology - ASCO
Member
American College of Physicians - ACP
Fellow
American Society of Hematology - ASH
Member

Hospital Affiliations

Baptist Medical Center JacksonvilleJacksonville, Florida